$AMS
AMERICAN SHARED HOSPITAL SERVICES Stock $ams

$ams Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924017104 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$7.056M	$5.216M
YoY Change	26.72%	5.91%
Cost Of Revenue	$4.588M	$3.073M
YoY Change	50.43%	1.86%
Gross Profit	$2.468M	$2.143M
YoY Change	-1.99%	12.32%
Gross Profit Margin	34.98%	41.09%
Selling, General & Admin	$1.896M	$1.879M
YoY Change	-4.63%	22.09%
% of Gross Profit	76.82%	87.68%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.523M	$1.334M
YoY Change	22.62%	-2.41%
% of Gross Profit	61.71%	62.25%
Operating Expenses	$1.896M	$1.879M
YoY Change	-4.63%	22.09%
Operating Profit	-$1.000K	-$85.00K
YoY Change	-99.69%	-186.73%
Interest Expense	$385.0K	$349.0K
YoY Change	38.99%	28.78%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	$3.737M	$21.00K
YoY Change	-1862.74%	-87.5%
Income Tax	-$31.00K	-$44.00K
% Of Pretax Income	-0.83%	-209.52%
Net Earnings	$3.602M	$119.0K
YoY Change	-3345.05%	-36.7%
Net Earnings / Revenue	51.05%	2.28%
Basic Earnings Per Share	$0.56	$0.02
Diluted Earnings Per Share	$0.55	$0.02
COMMON SHARES
Basic Shares Outstanding	6.330M	6.330M
Diluted Shares Outstanding	6.583M	6.576M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.24M	$12.79M
YoY Change	4.09%	-2.22%
Cash & Equivalents	$14.24M	$12.79M
Short-Term Investments
Other Short-Term Assets	$1.306M	$1.588M
YoY Change	20.81%	-7.41%
Inventory
Prepaid Expenses
Receivables	$8.606M	$6.429M
Other Receivables	$991.0K	$556.0K
Total Short-Term Assets	$25.64M	$21.37M
YoY Change	27.67%	9.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.64M	$26.93M
YoY Change	46.32%	19.46%
Goodwill	$1.265M	$1.265M
YoY Change	0.0%	0.0%
Intangibles	$78.00K	$78.00K
YoY Change	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$199.0K	$482.0K
YoY Change	423.68%	460.47%
Total Long-Term Assets	$35.19M	$28.76M
YoY Change	44.36%	19.95%
TOTAL ASSETS
Total Short-Term Assets	$25.64M	$21.37M
Total Long-Term Assets	$35.19M	$28.76M
Total Assets	$60.83M	$50.12M
YoY Change	36.82%	15.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$859.0K	$267.0K
YoY Change	189.23%	5.12%
Accrued Expenses	$3.548M	$2.335M
YoY Change	55.96%	5.23%
Deferred Revenue
YoY Change
Short-Term Debt	$3.950M	$2.400M
YoY Change
Long-Term Debt Due	$3.033M	$2.710M
YoY Change	139.95%	114.74%
Total Short-Term Liabilities	$13.34M	$10.78M
YoY Change	97.39%	105.16%
LONG-TERM LIABILITIES
Long-Term Debt	$12.05M	$12.89M
YoY Change	8.75%	12.17%
Other Long-Term Liabilities	$1.615M
YoY Change	2684.48%
Total Long-Term Liabilities	$12.05M	$12.89M
YoY Change	8.75%	12.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.34M	$10.78M
Total Long-Term Liabilities	$12.05M	$12.89M
Total Liabilities	$28.47M	$23.74M
YoY Change	52.13%	33.92%
SHAREHOLDERS EQUITY
Retained Earnings	$7.350M	$3.748M
YoY Change	137.4%	16.87%
Common Stock	$19.19M	$19.09M
YoY Change	2.09%	2.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.54M	$22.84M
YoY Change
Total Liabilities & Shareholders Equity	$60.83M	$50.12M
YoY Change	36.82%	15.1%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$3.602M	$119.0K
YoY Change	-3345.05%	-36.7%
Depreciation, Depletion And Amortization	$1.523M	$1.334M
YoY Change	22.62%	-2.41%
Cash From Operating Activities	$1.286M	-$1.865M
YoY Change	-62.76%	-205.91%
INVESTING ACTIVITIES
Capital Expenditures	$1.216M	$1.183M
YoY Change	-48.3%	466.03%
Acquisitions
YoY Change
Other Investing Activities	$363.0K
YoY Change
Cash From Investing Activities	-$853.0K	-$1.183M
YoY Change	-63.73%	466.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$164.0K
YoY Change		-77.53%
Cash From Financing Activities	1.011M	$2.282M
YoY Change	-299.02%	-383.83%
NET CHANGE
Cash From Operating Activities	1.286M	-$1.865M
Cash From Investing Activities	-853.0K	-$1.183M
Cash From Financing Activities	1.011M	$2.282M
Net Change In Cash	1.444M	-$766.0K
YoY Change	143.51%	-202.41%
FREE CASH FLOW
Cash From Operating Activities	$1.286M	-$1.865M
Capital Expenditures	$1.216M	$1.183M
Free Cash Flow	$70.00K	-$3.048M
YoY Change	-93.64%	-296.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	100000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	100000	usd
CY2024Q1	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	250000	usd
CY2023Q4	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	250000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6330000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6330000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6300000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6300000
CY2024Q1	ams	Number Of Medical Centers NumberOfMedicalCenters	10	pure
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2024Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P8M
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	36000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-08789
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CA
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-2918118
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	601 Montgomery Street
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94111-2619
CY2024Q1	dei	City Area Code CityAreaCode	415
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	788-5300
CY2024Q1	dei	Security12b Title Security12bTitle	American Shared Hospital Services Common Stock, No Par Value
CY2024Q1	dei	Trading Symbol TradingSymbol	AMS
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6330000
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12792000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13690000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	250000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	118000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6429000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4343000	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	556000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	504000	usd
CY2024Q1	ams	Prepaid Maintenance Current PrepaidMaintenanceCurrent	821000	usd
CY2023Q4	ams	Prepaid Maintenance Current PrepaidMaintenanceCurrent	1275000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	517000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	526000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	21365000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	20456000	usd
CY2024Q1	ams	Property Plant And Equipment Net Excluding Land PropertyPlantAndEquipmentNetExcludingLand	26879000	usd
CY2023Q4	ams	Property Plant And Equipment Net Excluding Land PropertyPlantAndEquipmentNetExcludingLand	25844000	usd
CY2024Q1	us-gaap	Land Land	19000	usd
CY2023Q4	us-gaap	Land Land	19000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	1265000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1265000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	78000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	78000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	57000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	482000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	443000	usd
CY2024Q1	us-gaap	Assets Assets	50124000	usd
CY2023Q4	us-gaap	Assets Assets	48162000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	267000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	315000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	715000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	757000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1584000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1226000	usd
CY2024Q1	ams	Asset Retirement Obligation Related Party Current AssetRetirementObligationRelatedPartyCurrent	650000	usd
CY2023Q4	ams	Asset Retirement Obligation Related Party Current AssetRetirementObligationRelatedPartyCurrent	650000	usd
CY2024Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	1180000	usd
CY2023Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	1229000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	36000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	57000	usd
CY2024Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2400000	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2500000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	2710000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2084000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10779000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10779000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	12892000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11041000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	68000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	63000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	23739000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	21883000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	10763000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	10763000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	8330000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	8232000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3748000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3629000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	22841000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	22624000	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	3544000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	3655000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26385000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26279000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50124000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48162000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5216000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4925000	usd
CY2024Q1	us-gaap	Direct Operating Maintenance Supplies Costs DirectOperatingMaintenanceSuppliesCosts	513000	usd
CY2023Q1	us-gaap	Direct Operating Maintenance Supplies Costs DirectOperatingMaintenanceSuppliesCosts	486000	usd
CY2024Q1	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	1297000	usd
CY2023Q1	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	1357000	usd
CY2024Q1	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	1093000	usd
CY2023Q1	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	879000	usd
CY2024Q1	ams	Other Cost Of Operating Revenue Related Party OtherCostOfOperatingRevenueRelatedParty	170000	usd
CY2023Q1	ams	Other Cost Of Operating Revenue Related Party OtherCostOfOperatingRevenueRelatedParty	295000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	3073000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	3017000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	2143000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1908000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1879000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1539000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	349000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	271000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-85000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	98000	usd
CY2024Q1	ams	Interest And Other Income Loss InterestAndOtherIncomeLoss	106000	usd
CY2023Q1	ams	Interest And Other Income Loss InterestAndOtherIncomeLoss	70000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	21000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	168000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-44000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	65000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	100000	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-54000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-88000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	119000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	188000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6452000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6306000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6576000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6472000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	25625000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	96000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	100000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	25821000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26279000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	98000	usd
CY2024Q1	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	38000	usd
CY2024Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	95000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	65000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26385000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	65000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	100000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1334000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1367000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	38000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	18000	usd
CY2024Q1	ams	Noncash Lease Expense NoncashLeaseExpense	21000	usd
CY2023Q1	ams	Noncash Lease Expense NoncashLeaseExpense	88000	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	68000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	98000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	96000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2138000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	634000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-412000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-548000	usd
CY2024Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-1898000	usd
CY2023Q1	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-66000	usd
CY2024Q1	ams	Increase Decrease In Accounts Payable Accrued Liabilities And Deferred Revenue IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndDeferredRevenue	268000	usd
CY2023Q1	ams	Increase Decrease In Accounts Payable Accrued Liabilities And Deferred Revenue IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndDeferredRevenue	279000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-49000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-21000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-103000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1865000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1761000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1183000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	209000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1183000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-209000	usd
CY2024Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	164000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	730000	usd
CY2024Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	2500000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	-0	usd
CY2024Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2400000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2700000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2024Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	-0	usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	74000	usd
CY2024Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	38000	usd
CY2023Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2024Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	95000	usd
CY2023Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	-0	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	97000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2282000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-804000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-766000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	748000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13808000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12453000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13042000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13201000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	311000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	253000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	17000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	20000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1174000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12792000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13083000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	250000	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	118000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13042000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13201000	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	164000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5216000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4925000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1334000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1367000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	349000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	271000	usd
CY2024Q1	us-gaap	Interest Income Interest Earning Asset InterestIncomeInterestEarningAsset	111000	usd
CY2023Q1	us-gaap	Interest Income Interest Earning Asset InterestIncomeInterestEarningAsset	87000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-44000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	68000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	119000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	188000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	79135000	usd
CY2023Q4	ams	Property Plant And Equipment Gross Excluding Land PropertyPlantAndEquipmentGrossExcludingLand	81227000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	52256000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	55383000	usd
CY2024Q1	ams	Property Plant And Equipment Net Excluding Land PropertyPlantAndEquipmentNetExcludingLand	26879000	usd
CY2023Q4	ams	Property Plant And Equipment Net Excluding Land PropertyPlantAndEquipmentNetExcludingLand	25844000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1334000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1367000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	38000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	18000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	222000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	15602000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	222000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1992000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	3402000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	8272000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1033000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	540000	usd
CY2024Q1	ams	Longterm Debt Maturity Thereafter LongtermDebtMaturityThereafter	585000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15824000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	769000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	472000	usd
CY2024Q1	ams	Accrued Operating Costs Current AccruedOperatingCostsCurrent	489000	usd
CY2023Q4	ams	Accrued Operating Costs Current AccruedOperatingCostsCurrent	450000	usd
CY2024Q1	ams	Accrued Liabilites Other Current AccruedLiabilitesOtherCurrent	326000	usd
CY2023Q4	ams	Accrued Liabilites Other Current AccruedLiabilitesOtherCurrent	304000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1584000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1226000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	36000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	37000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	37000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	36000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	21000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	103000	usd
CY2024Q1	us-gaap	Sublease Income SubleaseIncome	-0	usd
CY2023Q1	us-gaap	Sublease Income SubleaseIncome	50000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	21000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	53000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	21000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	103000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y8M1D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y11M12D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0442	pure
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0554	pure
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	119000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	188000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6452000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6306000
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	124000
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	166000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6576000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6472000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	98000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	96000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	146000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	146000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.83
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y5M8D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	146000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.83
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M8D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	42000
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.86
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	95000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.76
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M29D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	50000
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.93
CY2023Q1	ams	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P7Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2000
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.9
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	143000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.8
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M3D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	26000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	48000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.73
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y6M3D

Files In Submission

Name	View Source	Status
ams-20240331_cal.xml	Edgar Link	unprocessable
0001437749-24-017104-index-headers.html	Edgar Link	pending
0001437749-24-017104-index.html	Edgar Link	pending
0001437749-24-017104.txt	Edgar Link	pending
0001437749-24-017104-xbrl.zip	Edgar Link	pending
ams-20240331.xsd	Edgar Link	pending
asha20240331_10q.htm	Edgar Link	pending
ex_617015.htm	Edgar Link	pending
ex_617016.htm	Edgar Link	pending
ex_617017.htm	Edgar Link	pending
ex_669330.htm	Edgar Link	pending
ex_671276.htm	Edgar Link	pending
ex_671277.htm	Edgar Link	pending
ex_671278.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
ams-20240331_def.xml	Edgar Link	unprocessable
ams-20240331_lab.xml	Edgar Link	unprocessable
ams-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
asha20240331_10q_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMS
AMERICAN SHARED HOSPITAL SERVICES Stock $ams

2024 Q2 Form 10-Q Financial Statement

#000143774924017104 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMS AMERICAN SHARED HOSPITAL SERVICES Stock $ams

2024 Q2 Form 10-Q Financial Statement

#000143774924017104 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMS
AMERICAN SHARED HOSPITAL SERVICES Stock $ams